within Pharmacolibrary.Drugs.ATC.A;

model A08AA62
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.0033333333333333335,
    adminDuration  = 600,
    adminMass      = 8 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.6,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0027833333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A08AA62</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>The fixed-dose combination of bupropion and naltrexone is used for weight management as an adjunct to diet and exercise in adults with obesity or overweight with at least one weight-related comorbidity. Bupropion is a norepinephrine-dopamine reuptake inhibitor and naltrexone is an opioid antagonist. The combination is currently approved and marketed under brand names such as Contrave.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters for an adult population based on published PK profiles of individual components, as no population PK models for the combination have been published.</p><h4>References</h4><ol><li><p>Bays, HE, et al., &amp; Tondt, J (2022). Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. <i>Obesity pillars</i> 2 100018–None. DOI:<a href=\"https://doi.org/10.1016/j.obpill.2022.100018\">10.1016/j.obpill.2022.100018</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37990711/\">https://pubmed.ncbi.nlm.nih.gov/37990711</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A08AA62;
